Gain of chromosome 1q21 and the gene expression-based GEP70 risk score are established prognostic markers for newly diagnosed Multiple Myeloma (MM) patients. Here we addressed the prognostic impact of these two markers in 81 relapsed/refractory (RR) MM patients treated with the CD38-antibody daratumumab. Fluorescence in situ hybridization for 1q21 was performed at initial presentation, while the GEP70 score was determined at initial presentation and prior to daratumumab treatment. While the GEP70 at initial presentation showed a trend for inferior survival, the GEP70 collected prior to daratumumab treatment was significantly associated with poor outcome (P < 0·05). The worst outcome was seen for patients who were positive for gain(1q) and classified as GEP70 high risk prior to daratumumab [progression-free (PFS) and overall survival (OS) of 0·3 years (95% CI: 0·15-1·4 years) and 0·8 years (95% CI: 0·5-1·9 years) respectively], while the median PFS and OS were not reached by patients without gain(1q) and GEP70 low-risk status. In conclusion, gain(1q) and the GEP70 are powerful prognostic markers for RR MM patients treated with daratumumab, and patients classified as high risk according to these markers experience shorter treatment response.

中文翻译：

---

Daratumumab在高危复发/难治性多发性骨髓瘤患者中：1q21染色体获得/扩增和GEP70状态对预后的不利影响。

1q21染色体的获得和基于基因表达的GEP70风险评分是新诊断的多发性骨髓瘤（MM）患者的预后指标。在这里，我们探讨了这两种标记物对用CD38抗体daratumumab治疗的81例复发/难治性（RR）MM患者的预后影响。1q21的荧光原位杂交是在最初呈报时进行的，而GEP70分数是在最初呈报时以及在daratumumab治疗之前确定的。最初出现GEP70时，生存率呈下降趋势，而在daratumumab治疗之前收集到的GEP70与不良预后显着相关（P <0·05）。对于获利（1q）呈阳性并且在daratumumab [无进展（PFS）和总生存期（OS）为0·3年（95％CI：0·15）之前被定为GEP70高风险的患者，观察到最差的结果。 -1·4年）和0·8年（95％CI：0·5-1·9年）]，而没有增益（1q）和GEP70低危状态的患者未达到中位PFS和OS 。总之，gain（1q）和GEP70是接受daratumumab治疗的RR MM患者的有力预后标志物，根据这些标志物被分类为高危患者的治疗反应更短。